For patients in SGN35-012 with B-cell NHL, median DOR was 3.9 (95% CI, 1.6-8.5) months for patients with CD30 ≥10% (n = 17) and 8.3 months (95% CI, 1.8-16.6) for those with CD30 <10% (n = 24; Fig. 3). This evidence concerns the gene TNFRSF8 and B-cell non-Hodgkin lymphoma.